Progress towards the development of a vaccine against congenital toxoplasmosis: identification of protective antigens and the selection of appropriate adjuvants

J. Alexander, C. W. Roberts, J. M. Brewer

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

We have recently established that vertical disease transmission from the mother to the foetus, as in humans and sheep, only occurs in BALB/c mice infected with Toxoplasma gondii for first time during pregnancy. Thus a previous infection generally gives life long immunity, as ideally, would an effective vaccine. Of three major fractions harvested from RH strain tachyzoites (membrane, soluble and excretory/secretory) the soluble fraction was found the most effective in reducing mortality and cyst burdens in adult mice. Further studies indicated that the choice of adjuvant could enhance this effect. Entrapment within non-ionic surfactant vesicles (NISV), but not Freund’s Complete Adjuvant, significantly enhanced the protection afforded by soluble antigen to adult mice as well as greatly increasing the T cell specific proliferative response, IFN-γ production and antibody levels. NISV are safe, stable, and inexpensive and promote TH1 and CD8+ lymphocyte activation. In BALB/c dams vaccinated with NISV entrapped soluble antigen and infected on day 12 of pregnancy with 20 tissue cysts of T. gondii (RRA strain), congenital infection was reduced from a control level of 50% to 12% in surviving offspring and foetal death from 50% to nil. The identification of protective antigens in the soluble fraction is well advanced.
LanguageEnglish
Title of host publicationToxoplasmosis
EditorsJudith E. Smith
Place of PublicationBerlin
PublisherSpringer-Verlag
Pages217-229
Number of pages13
VolumeH78
ISBN (Print)9783642785610
DOIs
Publication statusPublished - 1993

Publication series

NameNato ASI Subseries H:
PublisherSpringer-Verlag
Volume78
ISSN (Print)1010-8793

Fingerprint

Congenital Toxoplasmosis
Surface-Active Agents
Vaccines
Toxoplasma
Antigens
Cysts
Pregnancy
Fetal Death
Lymphocyte Activation
Infection
Antibody Formation
Immunity
Sheep
Fetus
T-Lymphocytes
Membranes
Mortality

Keywords

  • toxoplasmosis
  • antigens

Cite this

Alexander, J. ; Roberts, C. W. ; Brewer, J. M. / Progress towards the development of a vaccine against congenital toxoplasmosis : identification of protective antigens and the selection of appropriate adjuvants. Toxoplasmosis. editor / Judith E. Smith. Vol. H78 Berlin : Springer-Verlag, 1993. pp. 217-229 (Nato ASI Subseries H:).
@inbook{c324fdb745f04280b2c8f029daa22bde,
title = "Progress towards the development of a vaccine against congenital toxoplasmosis: identification of protective antigens and the selection of appropriate adjuvants",
abstract = "We have recently established that vertical disease transmission from the mother to the foetus, as in humans and sheep, only occurs in BALB/c mice infected with Toxoplasma gondii for first time during pregnancy. Thus a previous infection generally gives life long immunity, as ideally, would an effective vaccine. Of three major fractions harvested from RH strain tachyzoites (membrane, soluble and excretory/secretory) the soluble fraction was found the most effective in reducing mortality and cyst burdens in adult mice. Further studies indicated that the choice of adjuvant could enhance this effect. Entrapment within non-ionic surfactant vesicles (NISV), but not Freund’s Complete Adjuvant, significantly enhanced the protection afforded by soluble antigen to adult mice as well as greatly increasing the T cell specific proliferative response, IFN-γ production and antibody levels. NISV are safe, stable, and inexpensive and promote TH1 and CD8+ lymphocyte activation. In BALB/c dams vaccinated with NISV entrapped soluble antigen and infected on day 12 of pregnancy with 20 tissue cysts of T. gondii (RRA strain), congenital infection was reduced from a control level of 50{\%} to 12{\%} in surviving offspring and foetal death from 50{\%} to nil. The identification of protective antigens in the soluble fraction is well advanced.",
keywords = "toxoplasmosis, antigens",
author = "J. Alexander and Roberts, {C. W.} and Brewer, {J. M.}",
year = "1993",
doi = "10.1007/978-3-642-78559-7_23",
language = "English",
isbn = "9783642785610",
volume = "H78",
series = "Nato ASI Subseries H:",
publisher = "Springer-Verlag",
pages = "217--229",
editor = "Smith, {Judith E.}",
booktitle = "Toxoplasmosis",

}

Alexander, J, Roberts, CW & Brewer, JM 1993, Progress towards the development of a vaccine against congenital toxoplasmosis: identification of protective antigens and the selection of appropriate adjuvants. in JE Smith (ed.), Toxoplasmosis. vol. H78, Nato ASI Subseries H:, vol. 78, Springer-Verlag, Berlin, pp. 217-229. https://doi.org/10.1007/978-3-642-78559-7_23

Progress towards the development of a vaccine against congenital toxoplasmosis : identification of protective antigens and the selection of appropriate adjuvants. / Alexander, J.; Roberts, C. W.; Brewer, J. M.

Toxoplasmosis. ed. / Judith E. Smith. Vol. H78 Berlin : Springer-Verlag, 1993. p. 217-229 (Nato ASI Subseries H:; Vol. 78).

Research output: Chapter in Book/Report/Conference proceeding › Chapter

TY - CHAP

T1 - Progress towards the development of a vaccine against congenital toxoplasmosis

T2 - identification of protective antigens and the selection of appropriate adjuvants

AU - Alexander, J.

AU - Roberts, C. W.

AU - Brewer, J. M.

PY - 1993

Y1 - 1993

N2 - We have recently established that vertical disease transmission from the mother to the foetus, as in humans and sheep, only occurs in BALB/c mice infected with Toxoplasma gondii for first time during pregnancy. Thus a previous infection generally gives life long immunity, as ideally, would an effective vaccine. Of three major fractions harvested from RH strain tachyzoites (membrane, soluble and excretory/secretory) the soluble fraction was found the most effective in reducing mortality and cyst burdens in adult mice. Further studies indicated that the choice of adjuvant could enhance this effect. Entrapment within non-ionic surfactant vesicles (NISV), but not Freund’s Complete Adjuvant, significantly enhanced the protection afforded by soluble antigen to adult mice as well as greatly increasing the T cell specific proliferative response, IFN-γ production and antibody levels. NISV are safe, stable, and inexpensive and promote TH1 and CD8+ lymphocyte activation. In BALB/c dams vaccinated with NISV entrapped soluble antigen and infected on day 12 of pregnancy with 20 tissue cysts of T. gondii (RRA strain), congenital infection was reduced from a control level of 50% to 12% in surviving offspring and foetal death from 50% to nil. The identification of protective antigens in the soluble fraction is well advanced.

AB - We have recently established that vertical disease transmission from the mother to the foetus, as in humans and sheep, only occurs in BALB/c mice infected with Toxoplasma gondii for first time during pregnancy. Thus a previous infection generally gives life long immunity, as ideally, would an effective vaccine. Of three major fractions harvested from RH strain tachyzoites (membrane, soluble and excretory/secretory) the soluble fraction was found the most effective in reducing mortality and cyst burdens in adult mice. Further studies indicated that the choice of adjuvant could enhance this effect. Entrapment within non-ionic surfactant vesicles (NISV), but not Freund’s Complete Adjuvant, significantly enhanced the protection afforded by soluble antigen to adult mice as well as greatly increasing the T cell specific proliferative response, IFN-γ production and antibody levels. NISV are safe, stable, and inexpensive and promote TH1 and CD8+ lymphocyte activation. In BALB/c dams vaccinated with NISV entrapped soluble antigen and infected on day 12 of pregnancy with 20 tissue cysts of T. gondii (RRA strain), congenital infection was reduced from a control level of 50% to 12% in surviving offspring and foetal death from 50% to nil. The identification of protective antigens in the soluble fraction is well advanced.

KW - toxoplasmosis

KW - antigens

UR - https://doi.org/10.1007/978-3-642-78559-7

U2 - 10.1007/978-3-642-78559-7_23

DO - 10.1007/978-3-642-78559-7_23

M3 - Chapter

SN - 9783642785610

VL - H78

T3 - Nato ASI Subseries H:

SP - 217

EP - 229

BT - Toxoplasmosis

A2 - Smith, Judith E.

PB - Springer-Verlag

CY - Berlin

ER -

Alexander J, Roberts CW, Brewer JM. Progress towards the development of a vaccine against congenital toxoplasmosis: identification of protective antigens and the selection of appropriate adjuvants. In Smith JE, editor, Toxoplasmosis. Vol. H78. Berlin: Springer-Verlag. 1993. p. 217-229. (Nato ASI Subseries H:). https://doi.org/10.1007/978-3-642-78559-7_23

Access to Document